-
公开(公告)号：US20100291215A1
公开(公告)日：2010-11-18
申请号：US12845354
申请日：2010-07-28
CPC分类号： A61L31/046 , A61L24/0015 , A61L24/106 , A61L27/225 , A61L27/227 , A61L27/54 , A61L2300/236 , A61L2300/252 , A61L2300/412 , A61L2300/414 , A61L2300/45
摘要： Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
摘要翻译： 生物活性分子被包埋在基质内，用于受控递送这些化合物用于治疗性愈合应用。 基质可以由天然或合成的化合物形成。 捕获生物活性分子的主要方法是通过体外或体内在基质凝胶化过程中沉淀生物活性分子。 生物活性分子可以被修饰以降低其在基质中的有效溶解度，以便在基质内更有效地保留生物活性分子，例如通过胱氨酸结生长因子超家族内，特别是在TGF-bgr内的成员的去糖基化; 超家族 可以修饰基质以包括对不同生物活性分子具有结合亲和力的位点，例如用于肝素结合的位点。
-
公开(公告)号：US20070202178A1
公开(公告)日：2007-08-30
申请号：US11739607
申请日：2007-04-24
申请人： Jason Schense , Hugo Schmoekel , Jeffrey Hubbell , Franz Weber
发明人： Jason Schense , Hugo Schmoekel , Jeffrey Hubbell , Franz Weber
IPC分类号： A61K9/00
CPC分类号： A61L31/046 , A61L24/0015 , A61L24/106 , A61L27/225 , A61L27/227 , A61L27/54 , A61L2300/236 , A61L2300/252 , A61L2300/412 , A61L2300/414 , A61L2300/45
摘要： Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
摘要翻译： 生物活性分子被包埋在基质内，用于受控递送这些化合物用于治疗性愈合应用。 基质可以由天然或合成的化合物形成。 捕获生物活性分子的主要方法是通过体外或体内在基质凝胶化过程中沉淀生物活性分子。 可以修饰生物活性分子以降低其在基质中的有效溶解度，从而更有效地将其保留在基质内，例如通过胱氨酸结生长因子超家族内，特别是在TGFbeta超家族内的成员的去糖基化。 可以修饰基质以包括对不同生物活性分子具有结合亲和力的位点，例如用于肝素结合的位点。
-
公开(公告)号：US08309518B2
公开(公告)日：2012-11-13
申请号：US12845354
申请日：2010-07-28
IPC分类号： A61K38/18 , A61K38/36 , C07K14/495 , C07K14/51
CPC分类号： A61L31/046 , A61L24/0015 , A61L24/106 , A61L27/225 , A61L27/227 , A61L27/54 , A61L2300/236 , A61L2300/252 , A61L2300/412 , A61L2300/414 , A61L2300/45
摘要： Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
摘要翻译： 生物活性分子被包埋在基质内，用于受控递送这些化合物用于治疗性愈合应用。 基质可以由天然或合成的化合物形成。 捕获生物活性分子的主要方法是通过体外或体内在基质凝胶化过程中沉淀生物活性分子。 生物活性分子可以被修饰以降低其在基质中的有效溶解度，以便在基质内更有效地保留生物活性分子，例如通过胱氨酸结生长因子超家族内，特别是在TGF-bgr内的成员的去糖基化; 超家族 可以修饰基质以包括对不同生物活性分子具有结合亲和力的位点，例如用于肝素结合的位点。
-
-
搜索结果
3 条记录 (耗时 0.009 秒)